Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the director now directly owns 1,318,031 shares of the company’s stock, valued at $32,950,775. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of NASDAQ EXEL traded down $0.23 during trading hours on Friday, hitting $24.53. The company had a trading volume of 4,141,757 shares, compared to its average volume of 4,072,850. The company has a market cap of $7.45 billion, a PE ratio of 17.15, a PEG ratio of 0.77 and a beta of 2.22. The company has a current ratio of 8.50, a quick ratio of 8.41 and a debt-to-equity ratio of 0.01. Exelixis, Inc. has a 1-year low of $13.42 and a 1-year high of $25.19.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 12th. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. The company had revenue of $228.60 million during the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The firm’s revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.12 EPS. As a group, sell-side analysts predict that Exelixis, Inc. will post 1.04 EPS for the current fiscal year.
Several equities analysts have recently weighed in on EXEL shares. Oppenheimer set a $40.00 price target on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 15th. ValuEngine raised shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 1st. BidaskClub raised shares of Exelixis from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Finally, Zacks Investment Research cut shares of Exelixis from a “buy” rating to a “hold” rating in a research note on Monday, February 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $29.20.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Exelixis, Inc. (EXEL) Director Sells 5,000 Shares of Stock” was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/4224649/insider-selling-exelixis-inc-exel-director-sells-5000-shares-of-stock.html.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More: Why is the price-sales ratio important?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.